Taipei, Taiwan, 11 August2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for July 2025 reached NT$2,397 million, a decrease of 12% year-over-year (YoY) compared to same period last year. Lotus's July 2025 year-to-date (YTD) revenue stood at NT$11,874 million, representing a 2% YoY growth.
Lotus's Asia business saw 15% YoY growth in revenue in July 2025 YTD. This was mainly attributable to the successful integration of Teva operations in Thailand and a smooth takeover of Alpha Choay in Vietnam, which drove revenue in Southeast Asia to grow at 229% for the same time period. Export markets declined 10% YoY compared to July 2024 YTD, mainly due to peak sales timing of Lenalidomide shifting to Q4 in 2025, as well as the decline in Subuxone due to competition. We expect Lenalidomide to see a double-digit growth in USD terms for the full year in 2025.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com